NEUROGENE INC(NGNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NGNE NEUROGENE INC

Pre-Mkt 09-03 06:52:02 EDT

38.36

+0.49

+1.29%

High39.78	Low36.86	Vol252.96K
Open37.97	D1 Closing37.87	Amplitude7.71%
Mkt Cap767.64M	Tradable Cap435.04M	Total Shares20.01M
T/O9.66M	T/O Rate2.23%	Tradable Shares11.34M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NGNE","market":"US","secType":"STK","nameCN":"NEUROGENE INC","latestPrice":38.36,"timestamp":1788379200000,"preClose":37.87,"halted":0,"volume":252961,"delay":0,"changeRate":0.012939001848428888,"floatShares":11340900,"shares":20011400,"eps":-5.044019,"marketStatus":"Pre-Mkt","change":0.49,"latestTime":"09-03 06:52:02 EDT","open":37.97,"high":39.78,"low":36.8618,"amount":9655064.522434,"amplitude":0.077058,"askPrice":54.25,"askSize":100,"bidPrice":37.28,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-5.044019,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788442200000},"marketStatusCode":1,"adr":0,"listingDate":1394168400000,"exchange":"NASDAQ","adjPreClose":38.36,"postHourTrading":{"tag":"盘后","latestPrice":38.85,"preClose":38.36,"latestTime":"19:30 EDT","volume":7275,"amount":281520.62,"timestamp":1788391806365,"change":0.49,"changeRate":0.012774,"amplitude":0.012774},"volumeRatio":1.7621706061317937,"impliedVol":0.7229,"impliedVolPercentile":0.2231},"requestUrl":"/m/hq/s/NGNE/wiki","defaultTab":"wiki","newsList":[{"id":"2660489173","title":"Neurogene price target raised to $81 from $69 at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2660489173","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660489173?lang=en_us&edition=fundamental","pubTime":"2026-08-17 18:02","pubTimestamp":1786960962,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Debjit Chattopadhyay raised the firm’s price target on Neurogene (NGNE) to $81 from $69 and keeps a Buy rating on the shares. Th...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neurogene-price-target-raised-to-81-from-69-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neurogene-price-target-raised-to-81-from-69-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NGNE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660489148","title":"Neurogene price target lowered to $166 from $180 at Canaccord","url":"https://stock-news.laohu8.com/highlight/detail?id=2660489148","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660489148?lang=en_us&edition=fundamental","pubTime":"2026-08-17 18:02","pubTimestamp":1786960946,"startTime":"0","endTime":"0","summary":"Canaccord lowered the firm’s price target on Neurogene (NGNE) to $166 from $180 and keeps a Buy rating on the shares. The firm said its 2Q26 report...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neurogene-price-target-lowered-to-166-from-180-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neurogene-price-target-lowered-to-166-from-180-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NGNE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659165229","title":"Stifel Nicolaus Sticks to Their Buy Rating for Neurogene (NGNE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659165229","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659165229?lang=en_us&edition=fundamental","pubTime":"2026-08-13 23:35","pubTimestamp":1786635328,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Paul Matteis reiterated a Buy rating on Neurogene today and set a price target of $46.00. Matteis covers the Healthcare sec...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-sticks-to-their-buy-rating-for-neurogene-ngne-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-sticks-to-their-buy-rating-for-neurogene-ngne-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SF","NGNE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658298977","title":"Neurogene Price Target Raised to $81.00/Share from $69.00 by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2658298977","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658298977?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:40","pubTimestamp":1786538400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NGNE/analyst-ratings","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658765609","title":"Annexon Biosciences Q2 Net Loss Widens, Cash Runway Extended","url":"https://stock-news.laohu8.com/highlight/detail?id=2658765609","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658765609?lang=en_us&edition=fundamental","pubTime":"2026-08-12 18:12","pubTimestamp":1786529574,"startTime":"0","endTime":"0","summary":"Annexon Biosciences Q2 net loss widens, cash runway extendedOverviewU.S. neuroinflammatory drug developer's Q2 net loss widened yr/yr, loss per share roseCash and investments totaled $209.2 mln, runwa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL1N4490BC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTRX","BK4139","NGNE","BK4121","COYA","ANNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658263789","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2658263789","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658263789?lang=en_us&edition=fundamental","pubTime":"2026-08-12 13:30","pubTimestamp":1786512621,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Immunome (IMNM), Neurogene (NGNE) and Seer (SEER) wi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-295?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-295?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4563","NGNE","BK4121","SEER","IMNM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658416509","title":"Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Cardiff Oncology (CRDF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658416509","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658416509?lang=en_us&edition=fundamental","pubTime":"2026-08-12 07:20","pubTimestamp":1786490407,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Neurogene (NGNE) and Cardiff Oncology (CRDF). Neur...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-neurogene-ngne-and-cardiff-oncology-crdf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-neurogene-ngne-and-cardiff-oncology-crdf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NGNE","BK4588","BK4139","CRDF","XBI","XLV","BK4137","LABU","LU0128526141.USD","LU0029874061.USD","BK4585","BK4581","HCSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658801943","title":"Savara Q2 Loss Widens as Operating Expenses Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2658801943","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658801943?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:13","pubTimestamp":1786479231,"startTime":"0","endTime":"0","summary":"Savara Q2 loss widens as operating expenses riseOverviewUS rare respiratory drug developer's Q2 net loss widened from prior yearOperating expenses rose, driven by higher personnel costs and commercial","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL1N4480YW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","TARA","IE00BJJMRZ35.SGD","LU2242652126.USD","BK4559","LU0985481810.HKD","LU1868837136.USD","IE0002141913.USD","LU2125154778.USD","BK4532","FTXH","LU2133065610.SGD","LU1868837300.USD","LU0306806265.USD","LU0432979614.USD","IE00BFXG1179.USD","LU1670710661.SGD","LU2596442595.SGD","IE0009355771.USD","LU0868494617.USD","BK4585","IE00BFTCPJ56.SGD","BK4581","LU0237698245.USD","LU1670711123.USD","LU1868836757.USD","SVRA","LU1868836914.USD","BK4588","BK4007","IHE","LU0225771236.USD","LU1883839398.USD","LU1670711040.USD","LU0114720955.EUR","BMY","LU1093756325.SGD","LU1093756168.USD","LU1585245621.USD","LU2360032135.SGD","LU1261432733.SGD","LU2242646821.SGD","LU1868836591.USD","LU1989771016.USD","LU0061475181.USD","LU1323610961.USD","LU0267386448.USD","LU1670710588.SGD","NGNE","LU0321505439.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658911368","title":"Neurogene Inc : Canaccord Genuity Cuts Target Price to $166 from $180","url":"https://stock-news.laohu8.com/highlight/detail?id=2658911368","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658911368?lang=en_us&edition=fundamental","pubTime":"2026-08-11 23:12","pubTimestamp":1786461124,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nFWN44815N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGNE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658970759","title":"Neurogene Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2658970759","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658970759?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:00","pubTimestamp":1786449639,"startTime":"0","endTime":"0","summary":"Neurogene Inc reports results for the quarter ended June 30 - Earnings SummaryNeurogene IncNGNE.OQreported a quarterly adjusted loss of $1.53 per share for the quarter ended June 30, lower than the sa","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL8N44810E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658992997","title":"Neurogene Q2 Operating Expenses USD 36.67 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658992997","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658992997?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:45","pubTimestamp":1786448743,"startTime":"0","endTime":"0","summary":"Aug 11 (Reuters) - Neurogene Q2 net income USD -34.488 million.:((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))Source Date/Time = 11-AUG-202611:10:02.38 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nRSD5hWg1g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NGNE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658997922","title":"Neurogene Q2 EPS $(1.53) Misses $(1.39) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2658997922","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658997922?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:45","pubTimestamp":1786448725,"startTime":"0","endTime":"0","summary":"Neurogene (NASDAQ:NGNE) reported quarterly losses of $(1.53) per share which missed the analyst consensus estimate of $(1.39) by 10.07 percent. This is a 45.71 percent decrease over losses of $(1.05) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61104509/neurogene-q2-eps-1-53-misses-1-39-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658997610","title":"Neurogene Publishes Corporate Presentation Highlighting NGN-401 Gene Therapy Program for Rett Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2658997610","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658997610?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:43","pubTimestamp":1786448630,"startTime":"0","endTime":"0","summary":"Neurogene publishes corporate presentation highlighting NGN-401 gene therapy program for Rett syndromeNeurogene highlighted NGN-401 as a one-time gene therapy candidate for Rett syndrome, positioned a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL2Tg026:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658975569","title":"Neurogene Q2 Adjusted Loss Per Share Misses Estimates on Employee Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2658975569","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658975569?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:39","pubTimestamp":1786448351,"startTime":"0","endTime":"0","summary":"Neurogene Q2 adjusted loss per share misses estimates on employee costsOverviewUS biotech for rare neurological diseases reported Q2 adjusted loss per share missed analyst expectationsNet loss and ope","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL1N4480EZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","GANX","BK4139","NKTX","NGNE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658920419","title":"Neurogene Q2 FY26 Net Loss Widens to USD 34.49 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658920419","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658920419?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:30","pubTimestamp":1786447850,"startTime":"0","endTime":"0","summary":"Neurogene Q2 FY26 net loss widens to USD 34.49 millionNeurogene posted a Q2 net loss of USD 34.49 million, widening from USD 22.02 million a year earlier.R&D costs rose to USD 25.47 million from USD 1","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL7Zq4SR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658997829","title":"Neurogene Q2 Adjusted EPS USD -1.53 VS. Ibes Estimate USD -1.42","url":"https://stock-news.laohu8.com/highlight/detail?id=2658997829","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658997829?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:30","pubTimestamp":1786447801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nPLX78L85V:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NGNE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658299786","title":"Neurogene - Extends Cash Runway into Q1 2029 with $144 Mln Oversubscribed Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2658299786","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658299786?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:30","pubTimestamp":1786447801,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nPLX78L85V:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGNE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658299737","title":"Corrected-Neurogene Q2 EPS USD -1.53 (Removes Extraneous Word)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658299737","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658299737?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:30","pubTimestamp":1786447801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nPLX78L85V:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGNE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658992031","title":"Press Release: Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658992031","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658992031?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:30","pubTimestamp":1786447800,"startTime":"0","endTime":"0","summary":"of June 16, 2026, which demonstrated developmental milestones were gained. in a progressive, stepwise sequence, suggesting a restart of development. --  100% of participants  improved on the Clinical Global. milestone, consistent with the composite endpoint used to evaluate. --  47 total developmental milestones were gained for an average of. through 30 months with no plateau or loss of milestone observed. --  7 of 10 participants gained >=2 developmental milestones and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443382.USD","LU2237443465.HKD","LU2746668974.SGD","LU0149725797.USD","BK4585","LU0170899867.USD","LU0267386448.USD","LU2237443622.USD","BK4588","LU2237443549.SGD","LU2746668461.USD","BK4604","TM","IE00BKVL7J92.USD","LU1363072403.SGD","IE00B1BXHZ80.USD","IE00BHPRN162.USD","NGNE","LU0882574139.USD","BK4099","BK4006","BK4139","LU2237443895.HKD","LU2237443978.SGD","03160","IE00BZ1G4Q59.USD","LU0971096721.USD","BK4555","CMC","IE00BFXG1179.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657571642","title":"Neurogene Inc Expected to Post a Loss of $1.42 a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2657571642","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657571642?lang=en_us&edition=fundamental","pubTime":"2026-08-07 22:54","pubTimestamp":1786114485,"startTime":"0","endTime":"0","summary":"Neurogene Inc <NGNE.OQ> expected to post a loss of $1.42 a share - Earnings PreviewNeurogene IncNGNE.OQNGNE.Ois expected to  show no change in quarterly revenue when it reports  results on August 10 (","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL8N4441RT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neurogene.com","stockEarnings":[{"period":"1week","weight":-0.0013},{"period":"1month","weight":0.167},{"period":"3month","weight":0.3959},{"period":"6month","weight":0.7303},{"period":"1year","weight":0.9532},{"period":"ytd","weight":0.8621}],"compareEarnings":[{"period":"1week","weight":-0.0012},{"period":"1month","weight":0.0099},{"period":"3month","weight":0.0107},{"period":"6month","weight":0.138},{"period":"1year","weight":0.1951},{"period":"ytd","weight":0.1221}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"","yearOnYearQuotes":[{"month":1,"riseRate":0.583333,"avgChangeRate":0.03558},{"month":2,"riseRate":0.416667,"avgChangeRate":-0.018567},{"month":3,"riseRate":0.416667,"avgChangeRate":0.022217},{"month":4,"riseRate":0.307692,"avgChangeRate":-0.048366},{"month":5,"riseRate":0.538462,"avgChangeRate":0.007464},{"month":6,"riseRate":0.461538,"avgChangeRate":-0.058237},{"month":7,"riseRate":0.538462,"avgChangeRate":-0.047276},{"month":8,"riseRate":0.846154,"avgChangeRate":0.724623},{"month":9,"riseRate":0.307692,"avgChangeRate":-0.055805},{"month":10,"riseRate":0.416667,"avgChangeRate":0.020322},{"month":11,"riseRate":0.416667,"avgChangeRate":0.000025},{"month":12,"riseRate":0.583333,"avgChangeRate":0.147487}],"exchange":"NASDAQ","name":"NEUROGENE INC","nameEN":"NEUROGENE INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NEUROGENE INC(NGNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest NEUROGENE INC(NGNE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"NEUROGENE INC,NGNE,NEUROGENE INC股票,NEUROGENE INC股票老虎,NEUROGENE INC股票老虎国际,NEUROGENE INC行情,NEUROGENE INC股票行情,NEUROGENE INC股价,NEUROGENE INC股市,NEUROGENE INC股票价格,NEUROGENE INC股票交易,NEUROGENE INC股票购买,NEUROGENE INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NEUROGENE INC(NGNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest NEUROGENE INC(NGNE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}